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Abstract: 
Background  
Increasing numbers of people with diabetes are adopting exercise 
programmes. Fear of hypoglycaemia, hypoglycaemia itself, and injuries are 
major issues for many people with diabetes undertaking physical activity. 
The purpose of this study was to investigate the effects of type 1 diabetes 
mellitus on the risk of hypoglycaemia, glycaemic variability, exercise 
performance, changes in body composition, changes in insulin dosage and 
psychosocial wellbeing during a multi-day endurance exercise event.  
Methods  
Eleven participants (7 with type 1 diabetes, 4 with normal glucose 
tolerance) undertook a 15-day, 2300km cycling tour from Barcelona to 
Vienna. Data were prospectively collected using bike computers, 
continuous glucose monitors, body composition analysers and mood 
questionnaires.  
Results  
Mean blood glucose in riders with and without diabetes significantly 
reduced as the event progressed. Glycaemic variability and time spent in 
hypoglycaemia did not change throughout the ride for either set of riders. 
Riders with diabetes in the lowest quartile of sensor glucose values had 
significantly reduced power output. Percentage body fat also significantly 
fell. Hypo- and hyperglycaemia provoked feelings of anxiety and worry.  
Conclusions  
This is the first study to describe a real-time endurance event in type 1 
diabetes, and provides important new data which cannot be studied in 
laboratory conditions. Hypoglycaemia continues to occurs in spite of peer 
support and large reductions in insulin dose. Glycaemic variability is shown 
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as a potential barrier to participation in physical activity through effects on 
mood and psychological well-being.  
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Abstract 
Background 
Increasing numbers of people with diabetes are adopting exercise 
programmes. Fear of hypoglycaemia, hypoglycaemia itself, and injuries are 
major issues for many people with diabetes undertaking physical activity. The 
purpose of this study was to investigate the effects of type 1 diabetes mellitus 
on the risk of hypoglycaemia, glycaemic variability, exercise performance, 
changes in body composition, changes in insulin dosage and psychosocial 
wellbeing during a multi-day endurance exercise event.  
Methods 
Eleven participants (7 with type 1 diabetes, 4 with normal glucose tolerance) 
undertook a 15-day, 2300km cycling tour from Barcelona to Vienna. Data 
were prospectively collected using bike computers, continuous glucose 
monitors, body composition analysers and mood questionnaires.  
Results  
Mean blood glucose in riders with and without diabetes significantly reduced 
as the event progressed. Glycaemic variability and time spent in 
hypoglycaemia did not change throughout the ride for either set of riders. 
Riders with diabetes in the lowest quartile of sensor glucose values had 
significantly reduced power output. Percentage body fat also significantly fell. 
Hypo- and hyperglycaemia provoked feelings of anxiety and worry.  
Conclusions  
This is the first study to describe a real-time endurance event in type 1 
diabetes, and provides important new data which cannot be studied in 
laboratory conditions. Hypoglycaemia continues to occurs in spite of peer 
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support and large reductions in insulin dose. Glycaemic variability is shown as 
a potential barrier to participation in physical activity through effects on mood 
and psychological well-being. 
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Introduction  
 
Undertaking physical activity can be challenging for people with diabetes; in 
particular matching insulin delivery with insulin requirements to enable 
provision of metabolic substrate to exercising muscles1. Failure to do so can 
lead to hypoglycaemia, both during and after exercise. We aimed to 
investigate the incidence and timing of hypoglycaemia over a multi-day event 
in people with type 1 diabetes (T1DM). We also sought to assess glycaemic 
variability, and how power output, heart rate and speed correlate with 
glucose. We studied cyclists with and without T1DM who undertook the Team 
Blood Glucose Diabetes Grand Tour, riding from Barcelona to Vienna over 15 
days to increase diabetes awareness.   
 
The primary fuel used by exercising muscles for sub-maximal aerobic 
exercise is glucose, sourced from muscle glycogen stores2,3. As these stores 
are depleted, equilibrium between hepatic glucose production and glucose 
uptake at the exercising muscle is established4. 
 
Increased α-adrenergic receptor activation at the pancreatic islet during 
exercise reduces insulin secretion and increases the ratio of glucagon to 
insulin, enhancing hepatic glucagon sensitivity and increasing hepatic glucose 
output5. Skeletal muscle glucose uptake continues by insulin-independent 
translocation of glucose-transporter-4 (GLUT-4) receptors to the cell surface6. 
During anaerobic exercise, a 14-18 fold increase in catecholamines can 
precipitate a 7-8 fold increase in glucose production and muscle 
glycogenolysis7. 
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Exogenously administered insulin does not fall on commencement of exercise 
and increased insulin exposure reduces hepatic glucose production leading to 
increased risk of hypoglycaemia8. GLUT-4 transporters remain in place 
between 3 and 24 hours following exercise to replenish muscle glycogen 
stores and late hypoglycaemia, 6-15 hours post exercise, is common9. 
Furthermore, the risk of hypoglycaemia increases during exercise following 
antecedent hypoglycaemia (within 24 hours before exercise) due to blunted 
counterregulatory reponses10. People with T1DM may need to consume 
additional carbohydrate to avoid hypoglycaemia in subsequent exercise11. 
Hypoglycaemia during exercise can be difficult to identify as the symptoms 
(sweating and elevated heart rate) mimic those experienced during exercise. 
Hypoglycaemia is less likely to be identified during sleep following exercise12.  
 
Short bouts of intense anaerobic exercise in people with T1DM can result in 
hyperglycaemia. The insulin rise seen in post-anaerobic exercise in people 
without T1DM ensures muscle glycogen replenishment but is impaired in 
those with T1DM with resultant hyperglycaemia13.   
 
The purpose of this study was to investigate the effects of type 1 diabetes 
mellitus on glycaemic variability, the risk of hypoglycaemia, exercise 
performance, changes in body composition, and psychosocial wellbeing 
during a multi-day endurance exercise event. 
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Methods  
 
Participants were recruited from those taking part in the Team Blood Glucose 
Diabetes Grand Tour 2014; there were no exclusion criteria. The cyclists 
completed 15 days of riding between Barcelona and Vienna covering 2300km 
with 2 rest days on Days 6 and 12 (Table 1). On most days, the cyclists 
began cycling at around 08.00 am and had completed the day’s ride by 16.00 
pm. This study was approved by the Riverside NRES ethics committee 
(14/LO/1299). All participants gave written informed consent.   
 
Table 1: Routes, distances and total climb during the Diabetes Grand 
Tour 
Day Route Distance (Km) Climb (m) 
1 Barcelona to Gerona 139 2333 
2 Girona to Saint-Cyprien 143 2489 
3 Saint Cyprien to Palavas Les Flots 186 1222 
4 Palavas Les Flots to Carpentras 154 966 
5 Carpentras to Dignes Les Bains 161 3295 
6 Rest   
7 Dignes Les Bains to Auron 146 4040 
8 Auron to Alba 171 2572 
9 Alba to Bobbio 155 2683 
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10 Bobbio to Reggiolo 173 1525 
11 Reggiolo to Treviso 191 1277 
12 Rest   
13 Treviso to Arte Therme 150 2506 
14 Art Thereme to Klagenfurt 164 3906 
15 Klagenfurt to Graz 154 2517 
16 Graz to Annaburg 153 3393 
17 Annaburg to Vienna 139 1566 
 
 
All riders with T1DM (n=7) and without T1DM (n=4) wore continuous glucose 
monitors (CGM) throughout (Dexcom G4, San Diego, CA). Of those with 
diabetes, continuous subcutaneous insulin infusion (n=5) and multi-dose 
injections (n=2) were used. Measurements of capillary blood glucose were 
also recorded each day. CGM data were analysed to identify periods of 
hypoglycaemia. Three definitions of hypoglycaemia and subsequent blood 
glucose values were used; <70mg/dl, <60mg/dl and <50mg/dl. Further 
analyses assessed differences in the percentage of time spent in 
hypoglycaemia. Time periods for evaluation of percent time spent were 
defined according to time of day (0800-1600; 1600-0000; and 0000-0800) and 
stage of ride (Stage 1 - days 1-5; Stage 2 - days 7-11; and Stage 3 - days 13-
17) to evaluate any changes over the ride. Variation in glucose levels and in 
percent time in hypoglycaemia were analysed using a random effects linear 
regression model with diabetes status, time of day and stage of race as 
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independent variables. Glycaemic variability was analysed using CGM data 
and EasyGV (Oxford, UK) software. The glycaemic variability (measured by 
standard deviation (SD) and low blood glucose index (LBGI)) of the riders with 
and without diabetes was compared14. 
 
Body composition analysis was performed each morning using a Tanita body 
composition analyser (Tokyo, Japan). Body mass (kg), body fat percentage 
and fat free mass (kg) were recorded. All riders were asked to complete a 
standardised mood questionnaire daily, to list 5 emotions felt after each day’s 
ride, and to record thoughts and overall feelings15. 
 
Data on power output (watts), heart rate, speed (km/h), distance travelled 
(km) and altitude (m) were gathered using Garmin Edge 1000 (Olathe, KS, 
USA) bike computers. Data from the bike computers were matched to CGM 
from Dexcom G4 and all data were formatted to 5 minute averages. Change 
in glucose over each 5 minute period was correlated with change in power, 
speed and heart rate over the same 5 minute period. The data were exported 
into Golden Cheetah cycling analysis software (www.goldencheetah.org) and 
transferred to Microsoft Excel. 
 
GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla 
California USA, www.graphpad.com) and STATA 13.0 (StataCorp College 
Station, TX, USA: StataCorp LP) were used for statistical analysis and graph 
creation. Statistical significance was set at p<0.05. 
 
Page 10 of 30
https://mc.manuscriptcentral.com/jofdst
Journal of Diabetes Science and Technology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
Page 10 of 25 
 
 
 
Results 
 
Eleven people participated in the study; seven had T1DM and 4 did not. 
There were 9 male and 2 female riders with a mean age of 41 years (range 
26-49). The mean body mass on day 1 was 79 kg (range 66.6-98.6 kg) and 
the mean duration of diabetes was 12.7 years (range 3-25 years).  
 
The mean blood glucose value of the riders with (n=7) and without diabetes 
(n=4) was analysed over the 3 stages of ride. There was a significant 
reduction in mean blood glucose for the riders with diabetes from between 
Stage 1 and 2 (154.3±0.7 vs 149.9±0.7 mmol/L, p<0.001) but no change 
between Stage 2 and 3 (Fig 1A).  
 
For the riders without diabetes a significant decrease in mean blood glucose 
occurred between Stage 1 and 2 (104.8±0.4 vs 96.1±0.4 mmol/L, p<0.001) 
and between Stage 2 and 3 (96.1±0.4 vs 94.1±0.4 mmol/L, p<0.001) (Fig 1B).  
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Figure 1. Mean blood glucose levels during the Team Blood Glucose 
Diabetes Grand Tour. Mean blood glucose (± standard error of the mean, 
SEM) of all riders (A) with diabetes and (B) without diabetes during the 3 five-
day stages of the Diabetes Grand Tour. ** = p<0.01, *** = p<0.001 measured 
by Kruksal-Wallis test and Dunn’s multiple comparisons. 
 
The mean blood glucose changes for each individual with diabetes across a 
24 hour period for each stage is shown in Fig 2. 
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Figure 2. Blood glucose levels measured by continuous glucose 
monitoring during the Team Blood Glucose Diabetes Grand Tour. CGM 
glucose was measured in 7 riders with diabetes during (A) Stage 1, (B) Stage 
2 and, (C) Stage 3. Each coloured line represents a different participant with 
diabetes.  
 
Random effects modelling showed that the presence of diabetes significantly 
increased glucose, independently of stage or time of day (+47.5mg/dl, 
p=0.004) (Table 2). Relative to 8am-4pm, between 4pm-12am glucose was 
reduced by 6.8mg/dl (p<0.001) and by 8.3mg/dl between 12am-8am 
(p<0.001), both independently of diabetes status and stage.  Relative to 
Stage 1, glucose was reduced in Stage 2 by 5.4mg/dl (p<0.001) and in Stage 
3 by 4.9mg/dl (p<0.001), both independently of diabetes status and time of 
day (Table 2).  
 
There was evidence for significant interaction between diabetes status, time 
of day and Stage when interaction terms were successively introduced into 
the random effects model. For example, the negative effect of ‘4pm-12am’ 
was primarily apparent in those with diabetes (diabetes * ‘4pm-12am’ 
interaction: -5.9mg/dl, p<0.001) and this can be seen in Table 2 in the lower 
mean glucose levels for Stages 2 and 3 at 4pm-12am compared with 8am-
4pm in those with diabetes compared with the higher mean values for the 
equivalent comparisons in those without diabetes. On the other hand, 
diabetes reduced the negative effect of ‘12am-8am’ on glucose levels, with 
the independent effect of ‘12am-8am’ augmented to -13.5mg/dl (p<0.001) in 
the presence of a diabetes * ‘12am-8am’ interaction term, but with the 
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interaction term itself appearing positive (+7.0mg/dl, p<0.001). Diabetes also 
reduced the negative effect of Stage 3 on glucose levels, with the 
independent effect of Stage 3 augmented to -8.8mg/dl (p<0.001) in the 
presence of a diabetes * Stage 3 interaction term that was positive 
(+5.2mg/dl, p=0.001). As shown in Table 2, this positive effect of diabetes in 
Stage 3 was concentrated in the exercise period (8am to 4pm). Time of day 
and stage also interacted significantly, with the independent negative effects 
of time of day and Stage being primarily apparent at later times and stages 
(results not shown). 
 
 
Blood glucose (mg/dl) 
8am to 4pm 4pm to 12am 12am to 8am 
With diabetes 
(n=7) 
Stage 1 151.6 (1.1) 153.2 (1.3)  158.2 (1.3) 
Stage 2 154.6 (1.3)  146.0 (1.3)  149.0 (1.3) 
Stage 3 167.6 (1.3) 140.9 (1.3) 140.9 (1.1) 
Without diabetes 
(n=4) 
Stage 1 111.6 (0.5)  108.2 (0.5)  95.6 (0.4) 
Stage 2 98.3 (0.5)  99.2 (0.5) 90.5 (0.4) 
Stage 3 92.0 (0.4) 97.6 (0.5) 93.2 (0.5) 
 
Table 2. Blood glucose of cyclists in the Diabetes Grand Tour by stage 
and time period of the day.  Blood glucose, measured by continuous 
glucose monitoring, was measured in all riders undertaking the Diabetes 
Grand Tour over three five-day stages; each stage was separated by a rest 
day. Details of statistical results obtained from random effects modelling are 
described in the text. Data is expressed as mean (±SEM). 
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Mean percent times in hypoglycaemia were also investigated (Table 3). 
Independent effects of diabetes status, stage and time were again explored 
by random effects modelling, in this case within each definition of 
hypoglycaemia. With hypoglycaemia defined as blood glucose <70 and 
<60mg/dl there were no significant effects on percent time in hypoglycaemia. 
With hypoglycaemia defined as blood glucose <50mg/dl, the presence of 
diabetes had the only effect, increasing percent time in hypoglycaemia with 
an independent effect size of +0.64% (p=0.02). 
 
 
Percent (%) time with blood 
glucose: 
(with diabetes n=7) 
Percent (%) time with blood 
glucose: 
(without diabetes n=4) 
<70  
mg/dl 
<60  
mg/dl 
<50 
mg/dl 
<70  
mg/dl 
<60  
mg/dl 
<50 
mg/dl 
All 
Stages 
4.97 2.1 0.85 6.95 1.4 0.24 
Stage 1 4.44 1.9 0.75 4.99 0.74 0.1 
Stage 2 5.61 2.32 0.97 7.24 0.76 0.3 
Stage 3 5.05 2.11 0.85 9.06 2.77 0.35 
 
Table 3. Incidence of hypoglycaemia experienced by riders on the 
Diabetes Grand Tour. Hypoglycaemia, expressed as percentage time below 
blood glucose values of 70, 60 and 50 mg/dl by stage of the ride in cyclists 
taking part in the Diabetes Grand Tour is shown. Participants rode >2300km 
over three five-day stages; each stage was separated by a rest day. There 
were no statistical differences when analysed by random effects modelling. 
 
The SD of glucose in participants without diabetes were all within the normal 
reference range of <54mg/dl14. Riders with diabetes had SDs regularly more 
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than 54 suggesting more glycaemic variability. However, there was no 
significant difference between the standard deviations during each stage or 
each time period of the day. In addition, there were no significant differences 
in LBGI between stages in the riders (both those with diabetes and without 
diabetes). There were also no changes in LBGI for riders between each eight-
hour time period. During the event, the average daily insulin use was 
significantly reduced on ride days (0.31 units/Kg/day) compared to rest days 
(0.48 units/Kg/day, p<0.05) (Figure 3). 
 
 
Figure 3. Insulin use during the Diabetes Grand Tour. Mean units of 
insulin/Kg/day (±SEM) for n=3 riders with diabetes analysed by Mann-
Whitney test. 
 
For the 7 riders with diabetes there were no statistically significant 
correlations between change in glucose and change in power, speed and 
heart rate across the 15 days of the event. There was a significant positive 
correlation between heart rate and power for all the riders over the full length 
of the tour (r=0.47, p<0.001). Five of the riders with diabetes had adequate 
power recordings to assess power output within blood glucose quartiles of: 
Page 16 of 30
https://mc.manuscriptcentral.com/jofdst
Journal of Diabetes Science and Technology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
Page 16 of 25 
 
≤70mg/dl; 70–140mg/dl; 141–200mg/dl; and, >200mg/dl (Figure 4). When the 
blood glucose was ≤70mg/dl the mean power output was significantly lower 
compared to the 70–140mg/dl range (68.6±70 vs 114.4±1.1 watts, p≤0.001).  
 
  
Figure 4. Relationship between power output and glucose in people with 
diabetes. Mean (±SEM) power output of the riders with diabetes in specified 
glucose ranges.  *** = p<0.001 vs all other groups measured by Kruksal-
Wallis test and Dunn’s multiple comparisons test. 
 
Body composition analysis of all riders demonstrated a significant reduction in 
mean percentage body fat between Day 1 and Day 15 of the ride (17.2±2.4 vs 
15.7±50%, p≤0.05). There were no significant changes in body mass or fat 
free mass.  
Only 3 riders completed the mood questionnaire in full for each day. 
Questionnaire completion significantly reduced over the duration of the study 
(Figure 5). Words used to describe periods of hypoglycaemia which had 
affected the riders’ performance were ‘frustrated’, ‘angry’, ‘grumpy’, ‘upset’ 
and ‘emotional’ reflecting the negative feelings attributed to hypoglycaemia. 
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The extended comments boxes were often used to describe hypoglycaemia 
and how this affected mood and performance. 
 
Figure 5. Mood questionnaire completion. Number of participants 
completing mood questionnaires each day (A), and mean (±SEM) number of 
completed questionnaires per stage (B). * = p<0.05 measured by Kruksal-
Wallis test and Dunn’s multiple comparisons test. 
Hyperglycaemia provoked feelings of anxiety and worry with riders describing 
low mood, stress and frustration and one rider described having to stop the 
ride and use the support bus due to ‘unexplained’ hyperglycaemia. 
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Discussion 
 
This study is the first of its kind to use a multi-day endurance exercise event 
to assess the interactions between T1DM and exercise performance, mood 
and glycaemic control, with a comparator cohort with normal glucose 
tolerance. A substantial reduction in mean blood glucose was noted for both 
riders with and without diabetes over the duration of the ride, without 
increased hypoglycaemia, demonstrating the impact of endurance exercise in 
people with maintained homeostasis. Power output was significantly impaired 
during hypoglycaemia in the riders with diabetes, and hypo- and 
hyperglycaemia provoked feelings of worry and anxiety and were shown as a 
potential barrier to participation in physical activity.   
 
For the riders with diabetes, the 4.3mg/dl reduction in mean blood glucose 
from Stage 1 to Stage 2 could be attributed to a number of reasons. As the 
ride progressed there is likely to have been greater demand for metabolic 
substrate, and increased insulin sensitivity, thus increasing the risk of 
hypoglycaemia due to difficulty in matching exogenous insulin to carbohydrate 
on ride days. Other published data suggest insulin requirements are 
consistently reduced by 6-15% during exercise, however our data show that 
hypoglycaemia still occurred in spite of insulin dose reductions of around 
30%, suggesting that required insulin dose reductions may be well in excess 
of those previously estimated16,17. 
The significant reduction in percentage body fat may also partly explain the 
reduced mean blood glucose. Adiponectin, an adipocytokine secreted solely 
from adipocytes, levels are higher in people who are lean compared to those 
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who are obese18,19. Furthermore, adiponectin has been shown to have an 
insulin sensitising function via activation of AMP-activated kinase (AMPK) in 
both skeletal muscle and the liver by increasing skeletal muscle glucose 
uptake and reducing hepatic gluconeogenesis respectively20-22. Thus a 
decrease in percentage body fat and a rise in adiponectin could explain the 
fall in mean blood glucose.  
 
The decrease in mean blood glucose from Stage 1 to Stage 3 amongst the 
riders without diabetes was 10.6mg/dl. One study has shown a marked 
increase in postprandial glycaemia amongst volunteers with normal glucose 
tolerance during 3 days of physical inactivity23. Our study suggests that 
endurance exercise has a significant impact on the short-term glucose control 
of people without diabetes although it is important to note there were only 4 
riders in this group. The mechanism for this is a presumed increase in insulin 
sensitivity as the ride progressed, as suggested by the increased time spent 
with a reported sensor glucose <70mg/dl.  
 
Many exercise studies take place in controlled laboratory conditions, thus 
there is little evidence for people with T1DM on how to self-manage their 
diabetes during longer periods of intense exercise such as training camps or 
endurance feats like this ride24. This study, the first of its kind, provides initial 
data which will contribute to supporting people to manage their diabetes and 
improve performance.  
The effects of blood glucose levels on power output were inconclusive. 
Overall there was no correlation between a change in power output and a 
change in blood glucose however, when splitting the blood glucose into 
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quartiles, power output was significantly lower in the hypoglycaemic range. 
Low blood glucose would limit exercising muscles’ capacity to maintain work 
and has been shown to curtail both physical and cognitive performance in 
sport25. The present study adds some important data on the effects of low 
blood glucose on cycling power and performance in people with T1DM 
however a larger sample will be needed to further strengthen these 
conclusions.  
 
The collection and analysis of the mood questionnaires was an important 
aspect of the study as hypoglycaemia has frequently been identified as one of 
the strongest barriers to physical activity in people with T1DM26. Suboptimal 
glycaemic control was a major concern for many of the riders with diabetes 
before the ride and the pre-ride questionnaires stated many hoped to gain 
better knowledge of blood glucose control during endurance exercise. It is 
clear from the responses to the questionnaires that hypo- and hyperglycaemia 
had a profound impact on many of the riders to the point where one rider ‘did 
not complete the total distance of the day in order to gain better control’ - 
highlighting the potential of poor glucose control as a barrier to participation. 
There are number of potential reasons why the psychosocial data were 
incomplete including increased tiredness at the end of the day and time 
required to complete. Prevalence of depression is higher in adults with T1DM 
than the general population and those who are depressed often have worse 
medical outcomes27,28. This study provides pilot qualitative data which can be 
used a framework for future research exploring the inter-relationship between 
mood, activity and diabetes. 
This study is limited by a small number of participants and CGM data should 
be interpreted with caution as sensor accuracy can be poor, particularly in the 
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hypoglycaemic range29. In addition, the lack of carbohydrate and small 
number contributing to the insulin dosage data limit the interpretation of the 
glucose data. However, the strengths of the study lie in the large volume of 
CGM data collected for each participant and in the originality of the data. This 
is the first study to analyse data collected from 15 days of a real-time 
endurance event and it will add to the current literature which has very little 
describing the effects of endurance exercise on glycaemic control, mood and 
performance of people with T1DM.  
 
Conclusions 
 
People with diabetes undertaking exercise, and those trying to support them, 
are often reliant on anecdotal or trial-and-error methods of management. This 
preliminary study has shown the effects of endurance exercise on lowering 
the blood glucose of both people with and without diabetes, and also how this 
can contribute to an increased risk of hypoglycaemia. The study has 
additionally begun to explore the effects of blood glucose on power output 
during cycling and provided insightful data regarding the psychology of 
athletes with diabetes. This study lays the foundations for further research in 
the field of endurance exercise in T1DM.  
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Figure 1. Mean blood glucose levels during the Team Blood Glucose Diabetes Grand Tour. Mean blood 
glucose (± standard error of the mean, SEM) of all riders (A) with diabetes and (B) without diabetes during 
the 3 five-day stages of the Diabetes Grand Tour. ** = p<0.01, *** = p<0.001 measured by Kruksal-Wallis 
test and Dunn’s multiple comparisons.  
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Figure 2. Blood glucose levels measured by continuous glucose monitoring during the Team Blood Glucose 
Diabetes Grand Tour. CGM glucose was measured in 7 riders with diabetes during (A) Stage 1, (B) Stage 2 
and, (C) Stage 3. Each coloured line represents a different participant with diabetes.  
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Figure 3. Insulin use during the Diabetes Grand Tour. Mean units of insulin/Kg/day (±SEM) for n=3 riders 
with diabetes analysed by Mann-Whitney test.  
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Figure 4. Relationship between power output and glucose in people with diabetes. Mean (±SEM) power 
output of the riders with diabetes in specified glucose ranges.  *** = p<0.001 vs all other groups measured 
by Kruksal-Wallis test and Dunn’s multiple comparisons test.  
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Figure 5. Mood questionnaire completion. Number of participants completing mood questionnaires each day 
(A), and mean (±SEM) number of completed questionnaires per stage (B). * = p<0.05 measured by 
Kruksal-Wallis test and Dunn’s multiple comparisons test.  
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